Silver Nanoparticles Targeting the Drug Resistance Problem of Streptococcus dysgalactiae: Susceptibility to Antibiotics and Efflux Effect

Silver Nanoparticles Targeting the Drug Resistance Problem of Streptococcus dysgalactiae: Susceptibility to Antibiotics and Efflux Effect

Xehetasun bibliografikoak
Parent link:International Journal of Molecular Sciences
Vol. 23, iss. 11.— 2022.— [6024, 12 p. ]
Erakunde egilea: Национальный исследовательский Томский политехнический университет Исследовательская школа химических и биомедицинских технологий
Beste egile batzuk: Garibo Ruiz D. Diana, Nefedova E. Ekaterina, Shkil N. N. Nikolay, Shkil N. A. Nikolay, Vazquez-Gomez R. L. Roberto Luna, Pestryakov A. N. Aleksey Nikolaevich, Bogdanchikova N. Nina
Gaia:The present work is a continuation of our translational research focusing on the use of silver nanoparticles (AgNPs) to solve the global problem of antibiotic resistance. In vivo fieldwork was done with 300 breeding farm cows with serous mastitis. Ex vivo assays revealed that after cow treatment with the antibiotic drug Spectromast LCTM, S.dysgalactiae susceptibility to 31 antibiotics dropped by 22.9%, but after treatment with Argovit-CTM AgNPs, it was raised by 13.1%. This was explained by the fact that the percentage of isolates with an efflux effect after Spectromast LC treatment resulted in an 8% increase, while Argovit-C-treatment caused a 19% decrease. The similarity of these results to our previous results on S. aureus isolates from mastitis cows treated with the antibiotic drug Lactobay and Argovit-CTM AgNPs was shown. So, mastitis treatments with Argovit-CTM AgNPs can partially return the activity of antibiotics towards S.dysgalactiae and S. aureus, while, in contrast, treatments with antibiotic drugs such as Spectromast LC and Lactobay enhance bacterial resistance to antibiotics. The results of this work strengthen the hope that in the future the use of AgNPs as efflux pump inhibitors will recover the activity of antibiotics, and thus will preserve the wide spectrum of antibiotics on the market.
Argitaratua: 2022
Gaiak:
труды учёных ТПУ
электронный ресурс
drug resistance
Streptococcus dysgalactiae
AgNPs
efflux effect
translational research
устойчивость
лекарства
стрептококки
Sarrera elektronikoa:https://doi.org/10.3390/ijms23116024
Formatua: Baliabide elektronikoa Liburu kapitulua
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=668068
Deskribapena
Gaia:The present work is a continuation of our translational research focusing on the use of silver nanoparticles (AgNPs) to solve the global problem of antibiotic resistance. In vivo fieldwork was done with 300 breeding farm cows with serous mastitis. Ex vivo assays revealed that after cow treatment with the antibiotic drug Spectromast LCTM, S.dysgalactiae susceptibility to 31 antibiotics dropped by 22.9%, but after treatment with Argovit-CTM AgNPs, it was raised by 13.1%. This was explained by the fact that the percentage of isolates with an efflux effect after Spectromast LC treatment resulted in an 8% increase, while Argovit-C-treatment caused a 19% decrease. The similarity of these results to our previous results on S. aureus isolates from mastitis cows treated with the antibiotic drug Lactobay and Argovit-CTM AgNPs was shown. So, mastitis treatments with Argovit-CTM AgNPs can partially return the activity of antibiotics towards S.dysgalactiae and S. aureus, while, in contrast, treatments with antibiotic drugs such as Spectromast LC and Lactobay enhance bacterial resistance to antibiotics. The results of this work strengthen the hope that in the future the use of AgNPs as efflux pump inhibitors will recover the activity of antibiotics, and thus will preserve the wide spectrum of antibiotics on the market.
DOI:10.3390/ijms23116024

Antzeko izenburuak